Piramal deal will give Abbott India size Piramal, who is the chairman of Piramal Healthcare, said “the valuation of about nine times shows the. It took four hours for Ajay Piramal to negotiate a whopping $ billion valuation for his generics business with Abbott. Just how did he pull it off. Abbott to pay $ billion for unit of India’s Piramal Disagreements over valuation have prevented more deals from getting done. Abbott.

Author: Sazahn Yogis
Country: Qatar
Language: English (Spanish)
Genre: Sex
Published (Last): 19 February 2012
Pages: 54
PDF File Size: 10.17 Mb
ePub File Size: 5.38 Mb
ISBN: 362-6-38014-295-7
Downloads: 4421
Price: Free* [*Free Regsitration Required]
Uploader: Kajilkis

Some said prices of medicines will go up. It is increasingly a preferred choice for infrastructure and real estate developers as well.

Abbott to pay $3.7 billion for unit of India’s Piramal

BOdsal global drugmakers look to boost their presence in emerging markets. Abbott plans to fund the deal with cash on its balance sheet and said it would not change its earnings outlook for Abbott and other Big Pharma abbottt face the twin challenges of slow growth in the developed markets and maturing product pipelines that are getting harder to replenish with newer, blockbuster drugs, according to Chaudhuri.

On top of that, India is a growing market. Abbott said it was advised by Morgan Stanley, while Piramal said it did not have a financial advisor on the deal.

Drag according to your convenience. Wharton professor of healthcare management Patricia Danzon agrees. Get instant notifications from Economic Times Allow Not now.

India certainly offers a large and growing domestic market with rising incomes and increasing health insurance coverage, says Danzon. To see your saved stories, click on link hightlighted in bold. BOthe U. It is not so much a concern about the downside, but about how we maximize the opportunity.


The chunk of Piramal Healthcare being sold has a 4. Mexico, for example, is in the process of changing its regime to require generics to be bioequivalent, she says.

Many view private equity firms as villainous actors intent on the singular goal of profit. The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in Since then, further pharmaceutical deals have been expected, as global majors search for growth and low-cost production of generics, as patents on major branded drugs are set to expire.

The stigma of selling—that has been holding back promoters of Indian pharmaceutical companies—is gone after two large lucrative deals in the sector, said an investment banker who asked not to be named.

Abbott to pay 17K crore for Piramal generics business – The Economic Times

That is one reason pharmaceutical multinationals are doing deals with the relatively small number of well established Indian companies that have met international standards in manufacturing.

The Indian unit of Abbott, which is a listed company, has a abboht. Globalization is not just for manufacturers. Globally, Abbott also faces the pressure of playing catch-up with its bigger rivals. Its other businesses include third-party manufacturing and pathology laboratories.

The earlier regime recognized patents on pharmaceutical processes but not on pharmaceutical products, allowing companies to reverse-engineer copies of the branded and patented drugs of western companies.

Growth Through Overseas Expansion Globalization is not just for manufacturers.

However, companies like Abbott and others getting into new generic drug markets must be watchful of the changing lay of the land there as well, according to Danzon.


But that qbbott also changing, she says. It will, however, continue research in drug discovery through an affiliate company. Sumeet ChatterjeeBharghavi Nagaraju.

Log In or sign up to comment. BOis booming as governments battle rising healthcare costs. For consumers, the great value in generics is getting it cheaper. At the same time, hopes have receded of a wholly Indian pharmaceutical major emerging as a global player. Your Reason has been Reported to the admin.

Yet, Piramal investors are disappointed. Fill in your details: As a global MNC, Abbott does. It makes a lot of sense if they can pull off all the valuatio issues. It allows Abbott to commercialize two dozen Zydus Cadila drugs in 15 emerging markets.

There is intense speculation that Mr Piramal will buy companies in some of these segments. Are you a Business Owner?

Seven years after Piramal deal, Abbott way off revenue target

Shares in Mumbai-based Piramal closed Innovation From Book to Bank: Unlike in a promoter stake sale, in this case the money will some to the company.

But new Wharton research provides better insight into the benefits of PE buyouts.

By comparison, Cipla trades at about 4. My Saved Articles Sign in Sign up.